Novartis and Pfizer sign clinical development agreement

30-10-2018

Novartis and Pfizer sign clinical development agreement

ll28 / iStockphoto.com

Swiss pharmaceutical company Novartis has partnered with Pfizer, its American rival, in efforts to advance the treatment of non-alcoholic steatohepatitis (NASH).


Novartis, Pfizer, collaboration, global agreement, non-alcoholic steatohepatitis, fatty liver disease, inflammation, fibrosis, fast track, clinical study

LSIPR